Healing Spinal Cord LesionsWe want to give back a possibility of autonomy to the patient with spinal cord trauma.
Hemera’s therapy uses a particular cell type, autologous immune cells educated in vitro to best express their pro-regenerative capacity even in a hostile microenvironment such as that of spinal cord.
We have brought together the best skills to meet the urgent needs of patients still missing a cure
Hemera is a spin-off of the University of Verona and of the University of Milan, specialized in regenerative medicine for neurological diseases.
Hemera came into existence thanks to the incredibly encouraging results of preclinical studies in vitro and in vivo, with the goal of significantly improve the prospect and the quality of life of patients with acute spinal cord lesion.
To Social Investor, Venture Capitalist, and Philanthropists who want to support us
Become an investor
Diseases and accidents can leave a permanent mark on our life when there is not a cure. Hemera’s goal is to transform scientific discoveries in effective treatments and to bring research findings to the patient bedside as soon as possible.
We support the development of our cell therapy through an innovative form of widespread funding, aimed at raising the required capital from anyone who is interested in the development of new therapies for very disabling diseases and is looking for a truly socially responsible investment.
News and events
Stay informed on Hemera’s activities, follow the updates, the press review, the news, and the events in the dedicated section.
In the context of the "Healing the Incurable" Innovation Coffee, our CEO Cristiana Vignoli enthusiastically shared significant progress in the...
Significant Recognition for REMaST® Therapy, a New Perspective for Medullo-Injured Patients Hemera has been chosen among the most innovative...
The patients will be monitored for 12 months at three Centers of Excellence in Northern Italy. At the starting blocks is the prospective...
Stay informed on Hemera’s latest activities with our Newsletter.